scPharmaceuticals. has filed a patent for liquid pharmaceutical formulations containing furosemide or a pharmaceutically acceptable salt, along with excipients and a buffer. The patent also covers methods of treating congestion, edema, fluid overload, or hypertension in patients. GlobalData’s report on scPharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on scPharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. scPharmaceuticals's grant share as of September 2023 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230277558A1) describes unit liquid pharmaceutical formulations containing furosemide, a commonly used diuretic. The formulations are intended for the treatment of conditions such as congestion, edema, fluid overload, or hypertension.
Claim 35 outlines a formulation that includes furosemide, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer containing tromethamine or a salt thereof. The concentration of furosemide in the formulation ranges from 60 mg/mL to 250 mg/mL, and the pH is between 6.5 and 8.5.
Claim 36 presents a similar formulation, but with a lower concentration of furosemide (60 mg/mL to 200 mg/mL) and the inclusion of benzyl alcohol as an excipient. The pH range remains the same.
Claim 37 specifies that the pH of the liquid pharmaceutical formulation in claim 36 is between 7 and 8.
Claim 39 states that the amount of benzyl alcohol in the formulation of claim 36 ranges from 0.5% to 5% (w/w).
Claim 41 introduces the possibility of additional components in the formulation, such as water, a pH adjuster (e.g., potassium hydroxide, sodium hydroxide, or hydrochloric acid), and an osmolarity adjuster (e.g., sodium chloride or potassium chloride).
Claim 43 describes a method of treating congestion, edema, fluid overload, or hypertension by administering the unit liquid pharmaceutical formulation of claim 35 to a patient. Claim 47 specifies that the formulation can be administered by subcutaneous injection.
Claim 50 introduces a kit for the treatment of the mentioned conditions, which includes the unit liquid pharmaceutical formulation of claim 35. The kit can contain one or more units of the formulation.
The remaining claims provide further details on the composition, volume, and pre-loading of the formulation in medical devices such as needles and syringes, autoinjectors, and injection pens.
In summary, the patent describes unit liquid pharmaceutical formulations containing furosemide for the treatment of congestion, edema, fluid overload, or hypertension. The formulations include specific concentrations of furosemide, excipients, and buffers, and can be administered by subcutaneous injection. The patent also mentions the possibility of including additional components and provides options for different volumes and pre-loading in medical devices.
To know more about GlobalData’s detailed insights on scPharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
